Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene

被引：54

作者：

Colmenero, P

Liljeström, P

Jondal, M

机构：

[1] Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden

[2] Swedish Inst Infect Dis Control, Dept Vaccine Res, Solna, Sweden

来源：

GENE THERAPY | 1999年 / 6卷 / 10期

关键词：

tumor antigen; P815; Semliki Forest virus; viral vector;

D O I：

10.1038/sj.gt.3301004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The methylcholantrene-induced P815 mastocytoma tumor is derived from DBA/2 mice and expresses a weak tumor rejection antigen, P815A. The PIA gene, which encodes for the P815A antigen, is silent in most normal tissues with the exception of testis and placenta. These characteristics make P815 an interesting mouse model for the human MAGE-type tumor antigens. Recombinant Semliki Forest virus particles (rSFV) were constructed that expressed variants of the P815 antigen. Such particles, when used for vaccination, express the antigen only transiently since the viral vector is incapable of productive replication. Nevertheless, mice vaccinated with rSFV generated strong CTL responses and were protected against P815 tumor challenge.

引用

收藏

页码：1728 / 1733

页数：6

相关论文

共 56 条

[1] T-CELL PRIMING VERSUS T-CELL TOLERANCE INDUCED BY SYNTHETIC PEPTIDES [J].

AICHELE, P ;

BRDUSCHARIEM, K ;

ZINKERNAGEL, RM ;

HENGARTNER, H ;

PIRCHER, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :261-266

[2] IDENTIFICATION AND CHARACTERIZATION OF THE TUMOR-SPECIFIC P1A GENE-PRODUCT [J].

AMARCOSTESEC, A ;

GODELAINE, D ;

VANDENEYNDE, B ;

BEAUFAY, H .

BIOLOGY OF THE CELL, 1994, 81 (03) :195-203

[3] Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells [J].

Arienti, F ;

SuleSuso, J ;

Belli, F ;

Mascheroni, L ;

Rivoltini, L ;

Melani, C ;

Maio, M ;

Cascinelli, N ;

Colombo, MP ;

Parmiani, G .

HUMAN GENE THERAPY, 1996, 7 (16) :1955-1963

[4] Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus [J].

Berglund, P ;

QuesadaRolander, M ;

Putkonen, P ;

Biberfeld, G ;

Thorstensson, R ;

Liljestrom, P .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (17) :1487-1495

[5] Enhancing immune responses using suicidal DNA vaccines [J].

Berglund, P ;

Smerdou, C ;

Fleeton, MN ;

Tubulekas, I ;

Liljeström, P .

NATURE BIOTECHNOLOGY, 1998, 16 (06) :562-565

[6] SEMLIKI FOREST VIRUS EXPRESSION SYSTEM - PRODUCTION OF CONDITIONALLY INFECTIOUS RECOMBINANT PARTICLES [J].

BERGLUND, P ;

SJOBERG, M ;

GAROFF, H ;

ATKINS, GJ ;

SHEAHAN, BJ ;

LILJESTROM, P .

BIO-TECHNOLOGY, 1993, 11 (08) :916-920

[7]

BERGLUND P, 1998, VACCINE, V17, P508

[8]

Bour H, 1998, J IMMUNOL, V160, P5522

[9] Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization [J].

Boyle, JS ;

Koniaras, C ;

Lew, AM .

INTERNATIONAL IMMUNOLOGY, 1997, 9 (12) :1897-1906

[10] INDIVIDUAL-DIFFERENCES IN THE ORIENTATION OF THE CYTOLYTIC T-CELL RESPONSE AGAINST MOUSE-TUMOR P815 [J].

BRICHARD, VG ;

WARNIER, G ;

VANPEL, A ;

MORLIGHEM, G ;

LUCAS, S ;

BOON, T .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (03) :664-671

← 1 2 3 4 5 6 →